$1.98
−5.26%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.91
From 52W high−95.79%
Volume44288.00
Market cap$3.23M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.91
From 52W high
−95.79%
Volume
44288.00
Market cap
$3.23M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
22.0
MomentumView details →
1D Return
−5.26%
YTD Return
−93.63%
SummaryUpdated Jun 1, 2026
Eterna Therapeutics Inc. (NASDAQ:ERNA), formerly known as Brooklyn ImmunoTherapeutics, is a clinical-stage biopharmaceutical company founded in 1991 and based in Brooklyn, New York. The company focuses on developing innovative cancer treatments through immunotherapy and advanced gene-editing technologies. As a biotechnology firm in the oncology space, Eterna operates in the high-risk, high-reward pharmaceutical development sector where companies invest years and substantial capital to bring potentially life-saving treatments from laboratory research through clinical trials to market approval.
Similar companies
Latest newsMore news →
Ernexa Therapeutics announced that preclinical data on its ERNA-101 candidate will be presented at Nature Conferences' Next-Generation Cancer Therapeutics meeting co-hosted by MD Anderson Cancer Center in Houston on October 6, 2026.14d agoErnexa Therapeutics reported safety results for ERNA-101 across three IND-enabling studies, advancing toward a planned Q4 2026 IND filing.20d agoErnexa Therapeutics Inc. appointed Robert J. Spiegel, M.D. to its Board of Directors effective September 14, 2026.33d ago